Clinical Research Directory

Inclusion Criteria: * Adults aged ≥18 years * Clinically confirmed diagnosis of Irritable Bowel Syndrome documented in the medical record * Presence of recurrent gastrointestinal symptoms such as bloating, abdominal discomfort, gas, or bowel habit disturbances (constipation, diarrhea, or mixed pattern) considered clinically relevant by the participant * Ability to understand the study procedures and provide written informed consent * Willingness to participate for the full duration of the study (approximately 16 weeks) and attend study visits (T0, T1, and Tfinal) * Willingness to provide biological samples (blood and stool samples for microbiota analysis) according to the study protocol Exclusion Criteria: * Known or suspected organic gastrointestinal disease explaining the symptoms (e.g., inflammatory bowel disease, untreated celiac disease, gastrointestinal malignancy) * Presence of alarm symptoms such as unexplained gastrointestinal bleeding, significant unintentional weight loss, persistent fever, severe anemia, or signs of acute infection * Acute gastrointestinal infection at the time of screening * Use of antibiotics within the previous 4-8 weeks prior to baseline * Use of probiotic, prebiotic, or microbiota-modifying supplements within 4 weeks prior to baseline that cannot be discontinued * Planned major dietary changes or initiation of new treatments for gastrointestinal symptoms during the study period * Pregnancy or breastfeeding * Known allergy or hypersensitivity to any component of the investigational supplement * Any severe comorbid condition or circumstance that, in the opinion of the investigator, could increase risk to the participant or interfere with study results